Combined Insulin Deficiency and Endotoxin Exposure Stimulate Lipid Mobilization and Alter Adipose Tissue Signaling in an Experimental Model of Ketoacidosis in Subjects With Type 1 Diabetes: A Randomized Controlled Crossover Trial

Diabetes. 2016 May;65(5):1380-6. doi: 10.2337/db15-1645. Epub 2016 Feb 16.

Abstract

Most often, diabetic ketoacidosis (DKA) in adults results from insufficient insulin administration and acute infection. DKA is assumed to release proinflammatory cytokines and stress hormones that stimulate lipolysis and ketogenesis. We tested whether this perception of DKA can be reproduced in an experimental human model by using combined insulin deficiency and acute inflammation and tested which intracellular mediators of lipolysis are affected in adipose tissue. Nine subjects with type 1 diabetes were studied twice: 1) insulin-controlled euglycemia and 2) insulin deprivation and endotoxin administration (KET). During KET, serum tumor necrosis factor-α, cortisol, glucagon, and growth hormone levels increased, and free fatty acids and 3-hydroxybutyrate concentrations and the rate of lipolysis rose markedly. Serum bicarbonate and pH decreased. Adipose tissue mRNA contents of comparative gene identification-58 (CGI-58) increased and G0/G1 switch 2 gene (G0S2) mRNA decreased robustly. Neither protein levels of adipose triglyceride lipase (ATGL) nor phosphorylations of hormone-sensitive lipase were altered. The clinical picture of incipient DKA in adults can be reproduced by combined insulin deficiency and endotoxin-induced acute inflammation. The precipitating steps involve the release of proinflammatory cytokines and stress hormones, increased lipolysis, and decreased G0S2 and increased CGI-58 mRNA contents in adipose tissue, compatible with latent ATGL stimulation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Acylglycerol-3-Phosphate O-Acyltransferase / genetics
  • 1-Acylglycerol-3-Phosphate O-Acyltransferase / metabolism
  • Adult
  • Biopsy
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Cross-Over Studies
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / immunology*
  • Diabetes Mellitus, Type 1 / metabolism
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetic Ketoacidosis / immunology*
  • Diabetic Ketoacidosis / metabolism
  • Diabetic Ketoacidosis / pathology
  • Diabetic Ketoacidosis / prevention & control
  • Endotoxins / toxicity
  • Gene Expression Regulation / drug effects
  • Humans
  • Hyperglycemia / chemically induced
  • Hyperglycemia / prevention & control
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use
  • Insulin / administration & dosage
  • Insulin / therapeutic use
  • Insulin, Long-Acting / administration & dosage
  • Insulin, Long-Acting / therapeutic use
  • Insulin, Short-Acting / administration & dosage
  • Insulin, Short-Acting / therapeutic use
  • Lipolysis* / drug effects
  • Male
  • Models, Immunological*
  • Panniculitis / drug therapy
  • Panniculitis / immunology*
  • Panniculitis / metabolism
  • Panniculitis / pathology
  • Signal Transduction* / drug effects
  • Subcutaneous Fat, Abdominal / drug effects
  • Subcutaneous Fat, Abdominal / immunology*
  • Subcutaneous Fat, Abdominal / metabolism
  • Subcutaneous Fat, Abdominal / pathology
  • Young Adult

Substances

  • Cell Cycle Proteins
  • Endotoxins
  • G0S2 protein, human
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin, Short-Acting
  • insulin, long-acting, human
  • endotoxin, Escherichia coli
  • 1-Acylglycerol-3-Phosphate O-Acyltransferase
  • ABHD5 protein, human